Our legislative and regulatory priorities are guided by our vision to end polycystic kidney disease. All policy priorities must meet our four core standards:
1. Increase funding for PKD research to make available new treatments to patients.
2. Ensure that PKD patients receive adequate, appropriate, affordable and sustained access to health care throughout the course of life.
3. Influence and improve regulatory processes to ensure PKD therapies are produced efficiently and that they are safe, effective and available to all PKD patients.
4. Engage and empower the patient voice in policymaking, drug development and regulatory decision-making.